AXL vs BJRI

The company exhibits weak fundamental health with a Piotroski F-Score of 4/9, indicating borderline stability, and lacks an Altman Z-Score to confirm financial distress risk. Despite a recent strong price run-up (+44.8% 1Y), profitability is thin, growth is negative, and leverage is extremely high (Debt/Equity: 3.81). Valuation metrics are mixed, with a low P/S of 0.17 suggesting potential undervaluation, but elevated P/E of 23.66 and negative earnings growth raise concerns. Analysts concur with a 'hold' rating, aligning with the uncertain outlook.

BJRI's Piotroski F-Score of 4/9 indicates weak financial health, signaling distress in operational efficiency and capital structure. The absence of an Altman Z-Score raises concern about potential bankruptcy risk, especially given a dangerously high Debt/Equity ratio of 1.41 and extremely low liquidity ratios (Current Ratio: 0.36, Quick Ratio: 0.21). While the company shows strong earnings surprise history and recent EPS growth of 130.8% YoY, these gains are likely driven by one-time or cyclical factors, as evidenced by negative operating margins (-0.13%) and inconsistent profitability. The stock trades at a premium to its intrinsic value and Graham number, suggesting overvaluation despite modest revenue growth. Analysts recommend 'buy' but with limited conviction, as the technical trend is bearish and insider sentiment is neutral.